ADTX
Aditxt, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+7.35%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$6602.62
MomentumView details →
1D Return
+7.35%
YTD Return
−100.00%
RSI (14)
19.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$6602.62
RSI (14)
19.8
MomentumView details →
1D Return
+7.35%
YTD Return
−100.00%
SummaryUpdated Mar 1, 2026
Aditxt, Inc. (NASDAQ:ADTX) is a Richmond, Virginia-based biotechnology company that was incorporated in 2017 and went public in June 2020. Originally known as ADiTx Therapeutics, Inc., the company changed its name to Aditxt, Inc. in July 2021. The company focuses on developing innovative technologies to improve immune system health through immune mapping and reprogramming approaches. Aditxt operates in the highly specialized field of immunotherapy, working on both diagnostic tools and therapeutic interventions that could potentially transform how immune-related conditions are understood and treated.
Similar companies
Latest newsMore news →
Aditxt, Inc. amended its private placement of senior secured notes, adding a new investor, cancelling one existing note, and issuing two new additional notes with no net change to the aggregate principal amount.50d agoAditxt, Inc. amended its Note Purchase Agreement to increase the aggregate original principal amount of senior secured convertible notes from $6,254,355.17 to $6,638,970.55 and added a new investor.74d agoAditxt plans to spin off its wholly owned subsidiary Ignite into an independent public company via a newly formed holding company expected to be named Ignite Proteomics Inc.86d ago